<scp>HIV:</scp> is it now a thing of the past?

Effective antiviral therapy for human immunodeficiency virus (HIV) has substantially reduced HIV-associated morbidity and mortality for people living with HIV (PLWH). The use of antiviral therapies as prevention, most notably pre-exposure prophylaxis (PrEP) as well as treatment as prevention (TasP), has significantly reduced the number of new infections in those using these biomedical prevention approaches (PrEP) and their sexual partners (TasP). However, nearly one-quarter of new HIV infections globally occur in the Asia-Pacific region (approximately 300 000 per annum) with a substantial number of deaths annually. Despite therapeutic advances, the total number of PLWH has increased worldwide. Although antiviral therapy has substantially reduced HIV-specific morbidity and mortality and is associated with significantly increased longevity, PLWH experience higher rates of chronic comorbidities than the general population. It is important that preventative approaches such as immunisation against specific conditions, lifestyle modification, smoking cessation and cancer screening are optimised for PLWH. Physicians are likely to care for PLWH in almost all subspecialties including aged care. Recent data support the use of organ transplantation in PLWH including from donors who also have HIV infection. HIV is most certainly not 'a thing of the past'.

Authors

Institutions

Publication Details

Journal
Internal Medicine Journal
Published
2025-10-01
DOI
https://doi.org/10.1111/imj.70200
Primary Topic
HIV/AIDS Research and Interventions
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

HIV: is it now a thing of the past?

Jeffrey J. Post
Internal Medicine Journal
HIV/AIDS Research and Interventions
article

HIV: is it now a thing of the past?

Jeffrey J. Post
article en

Abstract

Effective antiviral therapy for human immunodeficiency virus (HIV) has substantially reduced HIV-associated morbidity and mortality for people living with HIV (PLWH). The use of antiviral therapies as prevention, most notably pre-exposure prophylaxis (PrEP) as well as treatment as prevention (TasP), has significantly reduced the number of new infections in those using these biomedical prevention approaches (PrEP) and their sexual partners (TasP). However, nearly one-quarter of new HIV infections globally occur in the Asia-Pacific region (approximately 300 000 per annum) with a substantial number of deaths annually. Despite therapeutic advances, the total number of PLWH has increased worldwide. Although antiviral therapy has substantially reduced HIV-specific morbidity and mortality and is associated with significantly increased longevity, PLWH experience higher rates of chronic comorbidities than the general population. It is important that preventative approaches such as immunisation against specific conditions, lifestyle modification, smoking cessation and cancer screening are optimised for PLWH. Physicians are likely to care for PLWH in almost all subspecialties including aged care. Recent data support the use of organ transplantation in PLWH including from donors who also have HIV infection. HIV is most certainly not 'a thing of the past'.

Internal Medicine JournalVol. 55(12)
UNSW Sydney (AU), Albion Centre (AU), Prince of Wales Hospital (AU)
University of New South Wales
Openalex Percentile: Top 68%
HIV/AIDS Research and Interventions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.